大脑静脉血栓症和直接口服抗凝剂:一篇评论
Johanna Umurungi1, Francesca Ferrando2, Daniela Cilloni1
1Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
Journal of clinical medicine
|August 29, 2024
概括
直接口服抗凝剂 (DOAC) 显示出治疗脑静脉血栓症 (CVT) 的前景. 虽然有效和安全,但需要进一步的研究来确定它们在继续教育管理中的作用.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大脑静脉血栓形成 (CVT) 是一种罕见的脑血管事件,呈现方式可变.
- 早期诊断CVT可以改善患者的治疗结果.
- 目前的CVT管理依赖于肝素,其次是维生素K抗剂 (VKAs).
研究的目的:
- 审查关于在CVT中使用直接口服抗凝剂 (DOAC) 的文献.
- 为了评估DOACs的疗效和安全性,与CVT治疗的VKAs相比.
- 评估DOAC在继续教育管理中的可管理性和潜在优势.
主要方法:
- 在CVT中对DOAC研究的文献综述.
- 对DOAC与VKA的疗效和安全数据的分析.
- 评估DOAC的可管理性和预防潜力.
主要成果:
- 在静脉血栓栓塞治疗中,DOACs的疗效与VKAs相当.
- DOAC 具有与 VKA 相似的安全概况.
- 由于监控要求减少,DOACs提供了更好的管理能力.
结论:
- 初步研究表明,DOAC在CVT治疗中是有效和安全的.
- 在可管理性和潜在的预防方面,DOACs具有优势.
- 需要进行额外的研究才能将DOAC完全整合到标准的CVT治疗方案中.
更多相关视频
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57


